Designer Baby Companies Are in Turmoil

Why It Matters

The closures signal that investor appetite for germline‑editing ventures remains fragile amid regulatory bans and reputational risk, reshaping biotech funding strategies.

Key Takeaways

• Bootstrap Bio shut down after exhausting its funding
• Manhattan Genomics closed due to co‑founder governance conflict
• Federal arrest of Bootstrap’s chief science officer added scandal
• Germline editing remains illegal in US, limiting commercial pathways
• Former Manhattan Genomics founder launched Origin Genomics to pursue gene correction

Pulse Analysis

The promise of germline editing—altering DNA in human embryos to prevent disease—has long been shadowed by ethical controversy and strict regulation. The 2018 He Jiankui experiment, which produced the world’s first gene‑edited babies, sparked global outrage and resulted in a three‑year prison sentence for the Chinese scientist. Since then, most jurisdictions, including the United States, have prohibited initiating pregnancies with edited embryos, citing concerns over off‑target effects and the slippery slope toward designer‑baby enhancements.

Against this backdrop, Bootstrap Bio and Manhattan Genomics entered the market in 2024 with ambitious claims to develop safe, disease‑preventing embryo edits. Both attracted early venture interest, yet Bootstrap Bio’s cash burn outpaced investor commitment, and a high‑profile criminal charge against its chief science officer eroded credibility. Manhattan Genomics, despite assembling a star advisory board, collapsed after internal governance disputes between co‑founders, prompting one founder to launch Origin Genomics as a successor. These setbacks underscore the difficulty of securing sustained capital for technologies that sit at the intersection of cutting‑edge science and profound societal debate.

The fallout reverberates across the biotech ecosystem. Investors are now more cautious, demanding clear regulatory pathways and robust governance before backing germline‑editing ventures. Meanwhile, researchers continue to refine CRISPR and base‑editing tools, but commercial translation may shift toward somatic therapies—treatments that affect only the patient—where regulatory approval is clearer. Policymakers, ethicists, and industry leaders must collaborate to define responsible frameworks, lest the field’s momentum stall and the potential health benefits of precise genetic correction remain unrealized.